Nuvelo Announces Publication of Preclinical Study Results
Demonstrating the Potential of NTB-A as a New Target for Leukemia
and Lymphomas
SAN CARLOS, Calif., June 05, 2007 /PRNewswire-FirstCall/ --Nuvelo, Inc. today announced the publication of data from apreclinical study of novel monoclonal antibodies against thecell-surface protein NTB-A. The data demonstrate that NTB-A is apotential new target for immunotherapy of B-cell malignanciesincluding
leukemia and lymphomas. The study, entitled "The lymphoidcell surface recepto...
Dasatinib Shows High Early Response Rate as First Treatment for
Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
CHICAGO, June 2, 2007 - An established second-linedrug for chronic myelogenous
leukemia has high response rates whengiven to newly diagnosed patients as their first therapy for thedisease, according to early results from a Phase II clinical trialat The University of Texas M. D. Anderson Cancer Center. "Patients taking dasatinib achieve complete cytogenetic response- absence of the...
Promising Results with Epratuzumab and Chemotherapy in Children
with Acute Lymphoblastic Leukemia
- Results from a Children's Oncology Group (COG) Study Presented atAmerican Society of Clinical Oncology Annual Meeting - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Immunomedics,Inc. , a biopharmaceutical company focused on developing monoclonalantibodies to treat cancer and other serious diseases, todayannounced that treatment with epratuzumab plus standardchemotherapy is feasible...
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial
in B-Cell Chronic Lymphocytic Leukemia
SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ -- ZymoGenetics,Inc. today announced that interim findings were presented from aPhase 1b clinical trial with atacicept in B-cell chroniclymphocytic
leukemia (B-CLL) at the American Society of ClinicalOncology (ASCO) 2007 annual meeting. The study included intravenousadministration of higher doses than had been tested in previousstudies. <...
Leukemic Cells Find Safe Haven in Bone Marrow
St. Jude study shows mesenchymal cells in bone marrow supply
leukemic cells with the amino acid asparagine, restoring thiscritical nutrient when it is depleted by the cancer drugasparaginase MEMPHIS, Tenn., March 22, 2007 /PRNewswire/ -- The cancer drugasparaginase fails to help cure some children with acutelymphoblastic
leukemia (ALL) because molecules released by certaincells in the bon...
Major Gene Study Uncovers Secrets of Leukemia
St. Jude Study Scans 350,000 Locations Across the Genome From 242Patients and Identifies New Mutations That Contribute to AcuteLymphoblastic
Leukemia, Suggesting New Targets for Improved Therapy MEMPHIS, Tenn., March 07, 2007 /PRNewswire/ -- Investigators atSt. Jude Children's Research Hospital have discovered previouslyunsuspected mutations that contribute to the formation of pediatricac...